News | July 10, 2023
Novavax's Nuvaxovid receives full marketing authorization in the EU
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Pfizer is likely to show GSK significant competition
European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
Subscribe To Our Newsletter & Stay Updated
